此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估静脉注射 ACU193 对早期阿尔茨海默病参与者的疗效和安全性的研究 (ALTITUDE-AD) (ALTITUDE-AD)

2026年11月10日 更新者:Acumen Pharmaceuticals

一项 2/3 期双盲、随机、安慰剂对照自适应设计试验,评估静脉注射 ACU193 在早期阿尔茨海默病中的疗效和安全性

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.

研究概览

地位

主动,不招人

研究类型

介入性

注册 (实际的)

542

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • British Columbia
      • Kelowna、British Columbia、加拿大
        • Okanagan Clinical Trials
    • Ontario
      • Ottawa、Ontario、加拿大
        • Hippocampe d/b/a Ottawa Memory Clinic
      • Toronto、Ontario、加拿大
        • Toronto Memory Program (TMP) (Neurology Research Inc.)
    • Quebec
      • Greenfield Park、Quebec、加拿大
        • MoCA Research and Innovations
      • Berlin、德国
        • Charité - Universitaetsmedizin Berlin
      • Cologne、德国
        • University Hospital of Cologne
      • Mannheim、德国
        • Zentralinstitut für seelische Gesundheit
      • Munich、德国
        • Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar
    • California
      • Carlsbad、California、美国、92011-4219
        • The Neurology Center of Southern California - Carlsbad
      • Fullerton、California、美国、92835
        • Neurology Center of North Orange County
      • Irvine、California、美国、92614
        • Irvine Medical Research
      • Long Beach、California、美国、90804
        • Healthy Brain Research
      • Santa Ana、California、美国、92705
        • Syrentis Clinical Research
      • Sherman Oaks、California、美国、91403-2131
        • CenExel - California Neuroscience Research Medical Group, Inc (CNR)
    • Connecticut
      • Norwalk、Connecticut、美国、06851-4903
        • Research Center for Clinical Studies, LLC
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、22031
        • Re:Cognition Health - Fairfax
    • Florida
      • Atlantis、Florida、美国、33462
        • JEM Research Institute
      • Bradenton、Florida、美国、34205
        • Bradenton Research Center
      • Coral Gables、Florida、美国、33135
        • Gil Fernandez-Yera, MD, PA
      • Delray Beach、Florida、美国、33445
        • Brain Matters Research
      • Homestead、Florida、美国、33032
        • Coral Clinical Research
      • Lady Lake、Florida、美国、32159
        • K2 Medical Research - Villages
      • Miami、Florida、美国、33126
        • Finlay Medical Research
      • Naples、Florida、美国、34105-8522
        • Aqualane Clinical Research
      • Ocala、Florida、美国、34470
        • Ocala Health - Family Care Specialists - Ocala I
      • Port Orange、Florida、美国、32127
        • Progressive Medical Research
      • Stuart、Florida、美国、34997
        • Alzheimer's Research and Treatment Center - Stuart
      • Tampa、Florida、美国、33607
        • K2 Medical Research - Tampa
      • The Villages、Florida、美国、32162
        • Charter Research - Lady Lake
      • Wellington、Florida、美国、33414
        • Alzheimers Research and Treatment Center - Wellington
      • Winter Park、Florida、美国、32789
        • Conquest Research
      • Winter Park、Florida、美国、32792
        • Charter Research - Winter Park
    • Georgia
      • Columbus、Georgia、美国、31909
        • Columbus Memory Center
      • Decatur、Georgia、美国、30030
        • CenExel - iResearch Atlanta
    • Illinois
      • Northbrook、Illinois、美国、60640
        • Office of Jeffrey S. Ross, MD
    • Massachusetts
      • Newton、Massachusetts、美国、02459
        • Boston Center for Memory
    • Mississippi
      • Hattiesburg、Mississippi、美国、39401-7246
        • Hattiesburg Clinic - Memory Center
    • New Hampshire
      • Portsmouth、New Hampshire、美国、03801
        • ActivMed Practices and Research
    • New Jersey
      • Springfield、New Jersey、美国、07081
        • The Cognitive and Research Center of New Jersey
      • Toms River、New Jersey、美国、08755
        • CenExel - Advanced Memory Research Institute of NJ
    • New York
      • Albany、New York、美国、12208
        • Neurological Associates of Albany
    • North Carolina
      • Matthews、North Carolina、美国、28105
        • AMC Research
    • Ohio
      • Cleveland、Ohio、美国、44195
        • Cleveland Clinic
    • Oregon
      • Portland、Oregon、美国、97210
        • Summit Research Network
    • Pennsylvania
      • Abington、Pennsylvania、美国、19001
        • Abington Neurological Associates
      • Norristown、Pennsylvania、美国、19462
        • Keystone Clinical Research
    • Rhode Island
      • East Providence、Rhode Island、美国、02914
        • Rhode Island Mood and Memory
    • Tennessee
      • Cordova、Tennessee、美国、38018
        • Neurology Clinic. P.C
      • Knoxville、Tennessee、美国、37920-1511
        • The Alliance for Multispecialty Research LLC (AMR)
    • Texas
      • Austin、Texas、美国、78757
        • Senior Adult Specialty Research
      • Beaumont、Texas、美国、77702
        • Gadolin Research, LLC
      • Dallas、Texas、美国、75231
        • Kerwin Medical Center
      • Bristol、英国
        • Re:Cognition Health - Bristol
    • Greater London
      • London、Greater London、英国
        • Re:Cognition Health - London
      • London、Greater London、英国
        • St. Pancras Clinical Research Ltd.
    • Hampshire
      • Winchester、Hampshire、英国
        • Re:Cognition Health - Winchester
    • Lanarkshire
      • Motherwell、Lanarkshire、英国
        • Neuroclin Glasgow
    • Lancashire
      • Preston、Lancashire、英国
        • Panthera Bio-Partners - Preston
    • Surrey
      • Guildford、Surrey、英国
        • Re:Cognition Health - Guildford
    • Yorkshire
      • Sheffield、Yorkshire、英国
        • Panthera Biopartners - Sheffield
      • Barcelona、西班牙
        • Fundacio ACE
      • Donostia / San Sebastian、西班牙
        • Policlínica Gipuzkoa
      • Getxo、西班牙
        • Cae Oroitu
      • Madrid、西班牙
        • Hospital Ruber
      • Seville、西班牙
        • Hospital Victoria Eugenia
      • Valencia、西班牙
        • Hospital Universitari i Politècnic La Fe
    • Barcelona
      • Sant Cugat del Vallès、Barcelona、西班牙
        • Hospital Universitari General de catalunya
    • Zaragoza
      • Cuarte de Huerva、Zaragoza、西班牙
        • Fundacion Neuropolis - Hospital Viamed Montecanal

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 90年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Body weight of at least 30 kilograms (kg) (66 pounds [lbs]) and no more than 160 kg (352 lbs) at Screening

  • Must consent to apolipoprotein E4 (APOE4) genotype status assessment

  • Must meet all of the following criteria

    1. National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or probable AD
    2. Screening score between 22 and 30 (inclusive) on the Mini-Mental State Examination (MMSE)
    3. Screening score of 0.5 or 1.0 on the Clinical Dementia Rating Global Score (CDR-GS) and Screening score ≥0.5 on the CDR Memory Box score
    4. Evidence of cerebral amyloid accumulation by either PET scan or CSF
  • If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses must be stable for at least three months (12 weeks) prior to Baseline and every attempt should be made to keep them at stable doses throughout the study

  • Must have a reliable informant or study partner who is willing and able to perform all the roles as specified in the study partner Informed Consent Form (ICF)

  • Female participants must be surgically sterile or be at least one-year post-menopausal. Male participants with a female partner of child-bearing potential must use adequate contraception

Exclusion Criteria:

  • Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI

  • MRI of the brain that is inconsistent with MCI or AD or results showing greater than four ARIA-H, presence of any ARIA-E, or superficial siderosis

  • History of significant or unstable neurological disease, other than AD, which may affect cognition or ability to complete the study, such as other dementias, serious infection of the brain, significant head trauma, uncontrolled seizures, stroke, or Parkinson´s disease

  • Current serious or unstable clinically important illness that, in the judgment of the site investigator, is likely to affect cognitive assessment including visual and hearing impairment or affect the participant's safety or ability to complete the study

  • Malignant disease in the last five years except for resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal posttreatment prostate-specific antibody (PSA)

  • Geriatric Depression Scale-Short Form (GDS-SF) score >10 or current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), criteria for major depressive disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the site investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study

  • Suicide risk, as determined by meeting any of the following criteria:

    1. Any suicide attempt or preparatory acts/behavior on the C-SSRS Baseline/Screening in the last six months
    2. Suicidal ideation in the last six months as defined by a positive response to Question 5 (Suicidal Ideation) on the C-SSRS Baseline/Screening
    3. Significant risk of suicide, as judged by the site investigator
  • Conditions that may affect cognitive assessments during the study

  • Alcohol use disorder and/or substance use disorder within the last five years

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg

Participants will receive sabirnetug, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period.

Intravenous sabirnetug

实验性的:DBT Period: sabirnetug 50 mg/kg

Participants will receive sabirnetug, 35 mg/kg, for the first two doses, followed by sabirnetug, 50 mg/kg, Q4W as an IV infusion during the DBT period.

Intravenous sabirnetug

安慰剂比较:DBT Period: Placebo

Participants will receive sabirnetug matching placebo, Q4W as an IV infusion during the DBT period.

Intravenous Placebo

实验性的:Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg

Participants will receive sabirnetug, 35 mg/kg, Q4W as an IV infusion during the OLE period.

Intravenous sabirnetug

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score
大体时间:Baseline up to Week 80

iADRS is a validated composite of cognition and function made up of Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living scale (ADCS-iADL). ADAS-Cog13 is a rater-administered instrument consisting of 13 items assessing cognitive function areas most typically impaired in AD. ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently. iADL-items score ranges from 0 to 59 (lower scores indicating greater impairment). The iADRS is calculated as a linear combination of total scores from the ADAS-Cog13 and ADCS-iADL. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance.

Baseline up to Week 80

次要结果测量

结果测量
措施说明
大体时间
出现治疗相关不良事件 (TEAE) 的参与者人数
大体时间:基线至第 80 周
基线至第 80 周
发生严重不良事件 (SAE) 和特别关注不良事件 (AESI) 的参与者人数
大体时间:基线至第 80 周
基线至第 80 周
因 TEAE 中断或退出的参与者人数
大体时间:基线至第 80 周
基线至第 80 周
具有抗药物抗体 (ADA) 和中和抗体的参与者人数
大体时间:基线至第 80 周
基线至第 80 周
通过磁共振成像 (MRI) 测量出现淀粉样蛋白相关影像学异常伴水肿/渗出 (ARIA-E) 和 ARIA 伴出血/含铁血黄素沉积 (ARIA-H) 的参与者人数
大体时间:基线至第 80 周
基线至第 80 周
一部分参与者中 ACU193 的 CSF 浓度
大体时间:直至第 76 周
直至第 76 周
通过正电子发射断层扫描 (PET) 在质粒体中测量淀粉样蛋白斑块负荷或沉积相对于基线的变化
大体时间:基线至第 76 周
基线至第 76 周
全脑体积、心室体积和选定感兴趣区域体积的体积磁共振成像 (vMRI) 相对于基线的变化
大体时间:基线至第 76 周
基线至第 76 周
脑脊液中淀粉样蛋白、Tau 蛋白和其他神经退行性生物标志物浓度相对于基线的变化
大体时间:基线至第 76 周
基线至第 76 周
一部分参与者脑脊液中淀粉样蛋白、Tau 蛋白和其他神经退行性生物标志物浓度较基线的变化
大体时间:基线至第 76 周
基线至第 76 周
淀粉样蛋白、Tau 蛋白和其他神经退行性生物标志物血液浓度相对于基线的变化
大体时间:基线至第 76 周
基线至第 76 周
与安慰剂相比,sabirnetug 对临床进展的影响使用 iADRS 测量的节省时间分析进行评估
大体时间:基线至第 80 周
基线至第 80 周
与安慰剂相比,sabirnetug 对临床进展的影响使用 ADCS-iADL 测量的节省时间分析进行评估
大体时间:基线至第 80 周
基线至第 80 周
与安慰剂相比,sabirnetug 对临床进展的影响使用 ADAS-Cog13 测量的节省时间的分析进行评估
大体时间:基线至第 80 周
基线至第 80 周
与安慰剂相比,sabirnetug 对临床进展的影响使用 CDR-SB 测量的节省时间分析进行评估
大体时间:基线至第 80 周
基线至第 80 周
与安慰剂相比,sabirnetug 对临床进展的影响使用 MMSE 测量的节省时间分析进行评估
大体时间:基线至第 80 周
基线至第 80 周
Sabirnetug 的血清浓度
大体时间:给药前和给药后长达 80 周的多个时间点
给药前和给药后长达 80 周的多个时间点
脑脊液 (CSF) 中 sabirnetug 的浓度
大体时间:直至第 76 周
直至第 76 周
通过测量脑脊液中的 sabirnetug-淀粉样蛋白-β 寡聚体 (AβO) 复合物来评估目标参与度
大体时间:直至第 76 周
直至第 76 周
Change from Baseline in ADCS-iADL Score
大体时间:Baseline up to Week 80

The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire to be answered by a participant's study partner, where a participant's performance level is rated over the last 4 weeks, based on a set of performance descriptions. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently, and include shopping, keeping appointments, traveling outside of the home, making a meal or snack, and reading and writing. The iADL-items score ranges from 0 to 59 with lower scores indicating greater impairment.

Baseline up to Week 80
Change from Baseline in ADAS-Cog13 Score
大体时间:Baseline up to Week 80

ADAS-Cog is a rater-administered instrument, designed to assess the severity of dysfunction in cognition, characteristic of persons with AD. The ADAS-Cog13, the cognitive subscale of the ADAS, consists of 13 items assessing cognitive function areas most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, and digit cancellation. The scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition.

Baseline up to Week 80
Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB)
大体时间:Baseline up to Week 80

The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment.

Baseline up to Week 80
Change from Baseline in Mini-Mental State Examination (MMSE)
大体时间:Baseline up to Week 80

MMSE is a standard staging and assessment tool in AD, designed for grading the cognitive state of individuals with AD. The scale comprises tasks concerning orientation, memory, attention, language, and praxis to evaluate an individual's cognitive state. MMSE total score ranges from 0 to 30, with lower scores indicative of greater cognitive impairment.

Baseline up to Week 80
Change from Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)
大体时间:Baseline up to Week 80

The QOL-AD tool is a 13-item assessment with each question scored on a 4-point scale where 1 = poor quality of life and 4 = excellent quality of life. Scores range from 13 to 52 with higher scores indicating better quality of life.

Baseline up to Week 80
Change from Baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) Score
大体时间:Baseline up to Week 80

NPI-Q is a validated questionnaire completed by informants about participants for whom they care. Each of the 12 NPI-Q domains contains a survey question (answered in Yes/No) that reflects the cardinal symptoms of that domain. If the domain response is "Yes," the informant then rates the severity of the symptoms present within the last month on a 3-point scale and the distress of the symptom using a 5-point scale. The total NPI-Q severity score is the sum of the individual severity scores for each symptom and ranges from 0 to 36, with higher scores indicating more severe behavioral impairment. The total NPI-Q distress score is the sum of the individual distress scores for each symptom and ranges from 0 to 60, with higher scores indicating greater caregiver distress.

Baseline up to Week 80
Change from Baseline in EuroQoL 5-Dimension 5-Level (EQ-5D-5L)
大体时间:Baseline up to Week 80

EQ-5D-5L is a self-report survey that measures quality of life. The EQ-5D-5L consists of an EQ-5D descriptive system and EQ visual analog scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels, each assigned a unique 1-digit number: no problems, slight problems, moderate problems, severe problems, and extreme problems. The digits are combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's health on a vertical visual analog scale, where the endpoints are labeled 0= the best health you can imagine, and 100= the worst health you can imagine.

Baseline up to Week 80
Change from Baseline in Resource Utilization in Dementia (RUD)
大体时间:Baseline up to Week 80

The RUD questionnaire is a standardized tool and the most widely used instrument for resource use data collection in dementia, enabling comparison of costs of care across countries with differing health care provisions. It is designed to collect data on formal and informal care resource use and to be useful in different care settings, across different countries and care systems, and in both clinical studies and observational cost-of-illness studies.

Baseline up to Week 80
Change from Baseline in Zarit Burden Interview (ZBI)
大体时间:Baseline up to Week 80

ZBI consists of 22 items. Twenty-one of the items are designed to measure several aspects of burden, whereas Item 22 is a global measure of burden. Response options for each item range from 0-4, and total scores range from 0-88, with higher scores indicating greater self-reported burden.

Baseline up to Week 80
Percentage of Participants with No Clinical Progression at One Year
大体时间:Baseline up to Week 80

No clinical progression in participants will be defined as no decline in CDR-SB score. The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment.

Baseline up to Week 80
Number of Participants with Suicidal Ideation and Behavior as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Baseline up to Week 80

The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

Baseline up to Week 80
Correlation Between sabirnetug Exposure with Clinical Efficacy Measures
大体时间:Baseline up to 80 weeks

Correlation between sabirnetug exposure and clinical outcomes (including iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) will be assessed in this study.

Baseline up to 80 weeks
Correlation Between Change in Biomarker that Reflect Disease Progression and Clinical Changes
大体时间:Up to 80 weeks

Assessment of the correlation between change in clinical outcomes (iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) and change in biomarker (amyloid PET) will be determined by computing Pearson's correlation coefficient for each treatment group.

Up to 80 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年2月29日

初级完成 (实际的)

2026年10月29日

研究完成 (估计的)

2026年12月1日

研究注册日期

首次提交

2024年3月13日

首先提交符合 QC 标准的

2024年3月21日

首次发布 (实际的)

2024年3月28日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅